Grifols SA
GRFS10.860USD
+0.080+0.74%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
7.39BMarktkapitalisierung
43.58KGV TTM
mehr Informationen über Grifols SA Unternehmen
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Unternehmensinformationen
BörsenkürzelGRFS
Name des UnternehmensGrifols SA
IPO-datumMay 17, 2006
CEOMr. Jose Ignacio (Nacho) Abia
Anzahl der mitarbeiter23833
WertpapierartDepository Receipt
GeschäftsjahresendeMay 17
AddresseParque Empresarial Can Sant Joan
StadtSANT CUGAT DEL VALLES
BörseNASDAQ Global Select Consolidated
LandSpain
Postleitzahl08174
Telefon34935710000
Websitehttps://www.grifols.com/
BörsenkürzelGRFS
IPO-datumMay 17, 2006
CEOMr. Jose Ignacio (Nacho) Abia
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Joerg Schuettrumpf
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
--
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Proprietary Director
Proprietary Director
--
--
Mr. Daniel Fleta Coit
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Ms. Montserrat Munoz Abellana
Ms. Montserrat Munoz Abellana
Independent Director
Independent Director
--
--
Mr. Inigo Sanchez-Asiain Mardones
Mr. Inigo Sanchez-Asiain Mardones
Independent Director
Independent Director
--
--
Ms. Susana Gonzalez Rodriguez
Ms. Susana Gonzalez Rodriguez
Independent Director
Independent Director
--
--
Mr. Jordi Balsells Valls
Mr. Jordi Balsells Valls
President - Plasma Procurement
President - Plasma Procurement
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Joerg Schuettrumpf
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
--
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Proprietary Director
Proprietary Director
--
--
Mr. Daniel Fleta Coit
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States/Canada
4.42B
56.67%
Rest of the World
1.71B
21.96%
European Union
1.21B
15.50%
Spain
457.59M
5.87%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Brandes Investment Partners, L.P.
9.97%
Capital World Investors
8.33%
Permian Investment Partners, LP
7.00%
Black Creek Investment Management, Inc.
4.91%
Armistice Capital LLC
3.59%
Other
66.19%
Aktionäre
Aktionäre
Anteil
Brandes Investment Partners, L.P.
9.97%
Capital World Investors
8.33%
Permian Investment Partners, LP
7.00%
Black Creek Investment Management, Inc.
4.91%
Armistice Capital LLC
3.59%
Other
66.19%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
27.38%
Hedge Fund
18.23%
Investment Advisor/Hedge Fund
6.83%
Research Firm
4.06%
Pension Fund
1.13%
Sovereign Wealth Fund
0.75%
Bank and Trust
0.14%
Family Office
0.03%
Other
41.44%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
304
150.62M
58.33%
-8.38M
2025Q1
318
151.56M
58.69%
-8.09M
2024Q4
317
145.36M
56.29%
-25.01M
2024Q3
302
144.07M
55.96%
-19.66M
2024Q2
298
148.36M
57.63%
-6.71M
2024Q1
295
140.29M
54.61%
+6.03M
2023Q4
303
126.55M
49.26%
-7.36M
2023Q3
316
123.59M
48.19%
-7.60M
2023Q2
331
119.70M
46.67%
-25.54M
2023Q1
347
120.97M
47.21%
-11.90M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Brandes Investment Partners, L.P.
25.74M
9.97%
+5.25M
+25.59%
Mar 31, 2025
Capital World Investors
21.52M
8.33%
+388.01K
+1.84%
Mar 31, 2025
Permian Investment Partners, LP
18.08M
7%
+1.89M
+11.70%
Mar 31, 2025
Black Creek Investment Management, Inc.
12.69M
4.91%
+1.44M
+12.79%
Mar 31, 2025
Armistice Capital LLC
9.28M
3.59%
-758.00K
-7.55%
Mar 31, 2025
Millennium Management LLC
8.57M
3.32%
-783.49K
-8.38%
Mar 31, 2025
Soleus Capital Management, L.P.
7.09M
2.75%
+484.40K
+7.33%
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.66M
1.42%
+275.63K
+8.15%
Mar 31, 2025
Harris Associates L.P.
3.44M
1.33%
-284.90K
-7.65%
Mar 31, 2025
Janus Henderson Investors
3.05M
1.18%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Brandes US Small-Mid Cap Value ETF
1.82%
Brandes International ETF
1.72%
Capital Group International Core Equity ETF
0.23%
iShares Biotechnology ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
SPDR S&P Kensho New Economies Composite ETF
0.04%
ActivePassive International Equity ETF
0.03%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Mehr Anzeigen
Brandes US Small-Mid Cap Value ETF
Anteil1.82%
Brandes International ETF
Anteil1.72%
Capital Group International Core Equity ETF
Anteil0.23%
iShares Biotechnology ETF
Anteil0.15%
ProShares Ultra Nasdaq Biotechnology
Anteil0.12%
Invesco Nasdaq Biotechnology ETF
Anteil0.12%
SPDR S&P Kensho New Economies Composite ETF
Anteil0.04%
ActivePassive International Equity ETF
Anteil0.03%
SPDR Portfolio Developed World ex-US ETF
Anteil0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
436.88M
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
May 25, 2021
GRFS.NB Interim Cash Dividend of gross USD 0.456586 paid on Jun 14, 2021 going ex on Jun 03, 2021
Jun 04, 2021
Jun 14, 2021
Jun 03, 2021
Oct 23, 2020
GRFS.NB Interim Cash Dividend of gross USD 0.201439 paid on Nov 09, 2020 going ex on Oct 30, 2020
Nov 02, 2020
Nov 09, 2020
Oct 30, 2020
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
